Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Veracyte (VCYT)

Veracyte Q3 revenue rises 29% to $115.9 million; raises 2024 revenue guidance

Positive Impact 4 of 5 earnings Written later

Veracyte reported third-quarter 2024 total revenue of $115.9 million, up 29% from a year earlier, and net income of $15.2 million, compared with a net loss of $29.6 million in the third quarter of 2023. The company raised its full-year 2024 total revenue guidance to $442 million to $445 million, from $432 million to $438 million previously.

Key points

  • Total revenue of $115.9 million, up 29% from $90.1 million; testing revenue of $109.5 million, up 34%
  • Diluted EPS of $0.19 (GAAP), compared with a loss of $0.41 per share a year earlier; non-GAAP diluted EPS of $0.33
  • Full-year 2024 total revenue guidance raised to $442 million to $445 million; year-end cash guidance raised to $280 million to $285 million
  • Third-quarter cash from operations of $30.0 million; cash and cash equivalents of $274.1 million at September 30, 2024

The filing

CompanyVeracyte (VCYT)
Form8-K, current report
Filed with the SECNov 6, 2024, 4:11 PM ET
Accession number0001384101-24-000160

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:54 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 06, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.